Adagio Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious disease. Co. is developing its primary product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. Adintrevimab is designed to be a neutralizing antibody for both the prevention and treatment of COVID-19. Co. is also evaluating additional neutralizing antibodies targeting the receptor binding domain, as well as other subdomains within the spike protein for COVID-19. The ADGI average annual return since 2021 is shown above.
The Average Annual Return on the ADGI average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADGI average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADGI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|